

Supporting Information

Rec. Nat. Prod. **9:4** (2014) 628-632

Studies on the Chemical Constituents from Marine Bryozoan *Cryptosula pallasiana*

**Xiang-Rong Tian^{*1}, Hai-Feng Tang^{*2}, Yu-Shan Li³, Hou-Wen Lin⁴,
Xiu-Yun Zhang¹, Jun-Tao Feng¹ and Xing Zhang¹**

¹*Research & Development Center of Biorational Pesticide, College of Plant Protection,
Northwest A&F University, Yangling 712100, China;*

²*Institute of Materia Medica, School of Pharmacy, Fourth Military Medical University, Xi'an
710032, China*

³*School of Traditional Chinese Medicines, Shenyang Pharmaceutical University, Shenyang
110016, China*

⁴*Department of Pharmacy, Renji Hospital, Affiliated to School of Medicine, Shanghai Jiao-
Tong University, Shanghai 200127, China*

Table of Contents	Page
S1: Detailed extraction and isolation procedures of compounds 1–14	3
S2: Spectral data of compounds 3–14	4
S3: HR-ESI-MS (positive) spectrum of compound 1	6
S4: EI-MS spectrum of compound 1	6
S5: ¹ H-NMR (500 MHz, CD ₃ OD ₃) spectrum of compound 1	7
S6: ¹³ C-NMR (125 MHz, CD ₃ OD ₃) spectrum of compound 1	7

* Corresponding author: E- Mail: tianxiangrong@163.com (X.-R. Tian); tanghaifeng71@163.com (H.-F. Tang)
Phone/Fax: +86-29-84774748.

S7: DEPT135 spectrum of compound 1	8
S8: HSQC spectrum of compound 1	8
S9: HMBC spectrum of compound 1	9
S10: ^1H - ^1H COSY spectrum of compound 1	9
S11: ESI-MS (positive) spectrum of compound 2	10
S12: EI-MS spectrum of compound 2	10
S13: ^1H -NMR (500 MHz, DMSO- d_6) spectrum of compound 2	11
S14: ^{13}C -NMR (125 MHz, DMSO- d_6) spectrum of compound 2	11
S15: DEPT135 spectrum of compound 2	12
S16: HSQC spectrum of compound 2	12
S17: HMBC spectrum of compound 2	13
S18: ^1H - ^1H COSY spectrum of compound 2	13

S1: Detailed extraction and isolation procedures of compounds **1–14**.

The fresh animals of *C. pallasiana* (20 kg), were extracted exhaustively with 95% EtOH at room temperature. The extract solution was concentrated in vacuo to yield a semi-solid (600 g), which was suspended in H₂O, and extracted with AcOEt and BuOH, and then the AcOEt extract (63 g) was partitioned between 90% MeOH and petroleum ether (1:1). The MeOH solution was adjusted to 80% MeOH and extracted with CCl₄ (1:1) to give CCl₄ extract (12.9 g). And then the MeOH solution was adjusted to 60% MeOH and extracted with CH₂Cl₂ (1:1) to afford CH₂Cl₂ extract (8.2 g). The CCl₄ extract and the CH₂Cl₂ extract were subjected to column chromatography (CC) over Sephadex LH-20 column (CHCl₃/MeOH, 1:1) to afford three fractions, respectively, and then the obtained six fractions were combined to yield three major fractions (Frs. A–C) based on TLC analysis. Fr. B eluted with MeOH/H₂O (10:90, 30:70, 50:50) on Reversed-phase Si gel to afford three Sub-Fractions (S-Frs. B1–B3). S-Fr. B1 was further purified by repeated CC over Sephadex LH-20 (CHCl₃/MeOH, 1:1), and then with preparative HPLC (MeOH/H₂O 10:90) to yield **1** (12.1 mg), **9** (26.6 mg), **10** (30.2 mg) and **11** (14.9 mg). S-Fr. B2 was further purified by repeated CC over Sephadex LH-20 (CHCl₃/MeOH, 1:1), and then with preparative HPLC (MeOH/H₂O 25:75) to afford **4** (22.1 mg), **6** (4.7 mg), **7** (16.5 mg), **8** (2.0 mg) and **12** (16.6 mg). S-Fr. B3 was subjected to repeated CC over Sephadex LH-20 (CHCl₃/MeOH, 1:1), and then with preparative HPLC (MeOH/H₂O 40:60) to give **2** (2.4 mg), **5** (4.8 mg), and **13** (9.0 mg). Fr. C was subjected to CC over Reversed-phase Si gel (MeOH/H₂O 55:45), and then further purified by preparative HPLC (MeOH/H₂O 40:60) to afford **3** (3.0 mg). Fr. A was subjected to CC over Reversed-phase Si gel (MeOH/H₂O 80:20), and then further purified by preparative HPLC (MeOH/H₂O 85:15) to afford **14** (13.2 mg).

S2: Spectral data of compounds **3–14**.

7-Bromo-2,4(1H,3H)-quinazolinedione (3): Light yellow solid, ^1H NMR (500 MHz, DMSO- d_6) δ : 11.36 (2H, *br s*, NH-1 and NH-3), 7.79 (1H, *d*, $J = 8.4$ Hz, H-5), 7.35 (1H, *d*, $J = 1.6$ Hz, H-8), 7.33 (1H, *dd*, $J = 8.4, 1.6$ Hz, H-5); ^{13}C NMR (125 MHz, DMSO- d_6) δ : 150.1 (C-2), 162.2 (C-4), 113.6 (C-4a), 129.0 (C-5), 125.2 (C-6), 128.2 (C-7), 117.8 (C-8), 142.0 (C-8a); EI-MS m/z : 242/240 $[\text{M}+2]^+ / [\text{M}]^+$ (100), 199/197 $[\text{M} + 2 - \text{CO} - \text{NH}]^+ / [\text{M} - \text{CO} - \text{NH}]^+$ (75), 172/170 (47), 144/142 (9), 105 (15), 90 (33), 63 (56), 53 (20).

***p*-Hydroxybenzaldehyde (4):** Colorless needle crystal (MeOH), mp 115-118 °C (dec); ^1H -NMR (CD $_3$ OD, 400 MHz) δ : 9.74 (1H, *s*, CHO), 7.76 (2H, *d*, $J = 8.8$ Hz, H-2, H-6), 6.89 (2H, *d*, $J = 8.8$ Hz, H-3, H-5); ^{13}C -NMR (CD $_3$ OD, 100 MHz) δ : 190.9 (CHO), 166.2 (C-4), 133.1 (C-2, C-6), 129.3 (C-1), 117.3 (C-3, C-5); EI-MS m/z (rel. int.): 121 $[\text{M}]^+$ (100), 93 (53), 74 (9), 65 (52).

Methylparaben (5): Colorless needle crystal (MeOH), mp 128-130 °C (dec); ^1H -NMR (CD $_3$ OD, 400 MHz) δ : 8.86 (2H, *d*, $J = 8.8$ Hz, H-2, H-6), 6.81 (2H, *d*, $J = 8.8$ Hz, H-3, H-5), 3.84 (3H, *s*, OCH $_3$); ^{13}C -NMR (CD $_3$ OD, 100 MHz) δ : 168.1 (CO), 163.5 (C-4), 132.8 (C-2, C-6), 122.2 (C-1), 116.1 (C-3, C-5), 52.2 (OCH $_3$); EI-MS m/z (rel. int.): 152 $[\text{M}]^+$ (56), 121 (100), 93 (34), 65 (34), 54 (10).

Benzamide (6): White amorphous powder; ^1H -NMR (DMSO- d_6 , 500 MHz) δ : 7.96 (1H, *br s*, NH), 7.87 (2H, *d*, $J = 7.3$ Hz, H-2, H-6), 7.52 (1H, *t*, $J = 7.2$ Hz, H-4), 7.45 (1H, *t*, $J = 7.2$ Hz, H-3, H-5), 7.35 (1H, *br s*, NH); ^{13}C -NMR (DMSO- d_6 , 125 MHz) δ : 134.3 (C-1), 127.4 (C-2, C-6), 128.2 (C-3, C-5), 131.2 (C-4), 167.8 (CO); EI-MS m/z : 121 $[\text{M}]^+$ (20), 71 (29), 62 (100), 44 (100); ESI-MS (+) m/z : 144 $[\text{M} + \text{Na}]^+$, 265 $[2\text{M} + \text{Na}]^+$.

Phenylacetamide (7): White amorphous powder; ^1H -NMR (CD $_3$ OD, 500 MHz) δ : 7.29 (4H, *dd*, $J = 7.3, 2.6$ Hz, H-2 or H-6, H-3, H-4, H-5), 7.23 (1H, *m*, H-2 or H-6), 3.30 (2H, *m*, CH $_2$); ^{13}C -NMR (CD $_3$ OD, 125 MHz) δ : 136.9 (C-1), 130.1 (C-2, C-6), 129.6 (C-3, C-5), 127.9 (C-4), 43.4 (CH $_2$), 177.0 (CO); EI-MS m/z : 135 $[\text{M}]^+$ (39), 91 (100), 65 (39), 52 (13), 45 (31); ESI-MS (+) m/z : 158 $[\text{M} + \text{Na}]^+$, 293.13 $[2\text{M} + \text{Na}]^+$.

4(3H)-Quinazolinon (8): White amorphous powder; mp 215-217 °C (dec); ^1H -NMR (CD $_3$ OD, 500 MHz) δ : 8.23 (1H, *d*, $J = 8.0$ Hz, H-5), 8.10 (1H, *s*, H-2), 7.84 (1H, *t*, $J = 7.5$ Hz, H-7), 7.70 (1H, *d*, $J = 8.0$ Hz, H-8), 7.56 (1H, *d*, $J = 7.6$ Hz, H-6); EI-MS m/z (rel. int.):

146 $[M]^+$ (100), 118 $[M - CO]^+$ (42), 103 $[M - CO - NH]^+$ (5), 90 (29), 76 (16), 62 (28), 51 (18), 44 (26).

Thymine (9): Light Yellow solid; mp 315-317 °C (dec); 1H -NMR (CD_3OD , 500 MHz) δ : 7.21 (1H, *s*, H-6), 1.84 (3H, *s*, H₃-5); ^{13}C -NMR (CD_3OD , 125 MHz) δ : 153.8 (C-2), 167.5 (C-4), 110.4 (C-5), 139.2 (C-6), 12.1 (5-CH₃).

Uracil (10): Light Yellow solid; mp 333-335 °C (dec); 1H -NMR ($DMSO-d_6$, 500 MHz) δ : 10.91 (2H, *s*, NH), 7.49 (1H, *d*, $J = 7.6$ Hz, H-6), 5.45 (1H, *d*, $J = 7.6$ Hz, H-5); ^{13}C -NMR ($DMSO-d_6$, 125 MHz) δ : 151.6 (C-2), 164.4 (C-4), 142.2 (C-5), 100.2 (C-6).

Hypoxanthine (11): Light Yellow solid; 1H -NMR ($DMSO-d_6$, 500 MHz) δ : 12.57 (1H, *br s*, NH), 8.10 (1H, *s*, H-2), 7.97 (1H, *s*, H-8), 7.28 (1H, *br. s*, OH); ^{13}C -NMR ($DMSO-d_6$, 125 MHz) δ : 144.6 (C-2), 158.3 (C-4), 119.3 (C-5), 155.5 (C-6), 140.4 (C-8); EI-MS m/z : 136 $[M]^+$ (100), 109 (11), 81 (21), 66 (7), 54 (42).

Tryptophan (12): White amorphous powder; mp 287-290 °C (dec); 1H -NMR ($DMSO-d_6$, 500 MHz) δ : 11.04 (1H, *s*, COOH), 7.57 (1H, *d*, $J = 7.8$ Hz, H-4), 7.35 (1H, *d*, $J = 8.1$ Hz, H-7), 7.25 (1H, *s*, H-2), 7.05 (1H, *t*, 7.4 Hz, H-6), 6.96 (1H, *t*, $J = 7.5$ Hz, H-5), 3.53 (1H, *m*, H-2'), 3.32 (1H, *d*, $J = 13.1$ Hz, H-1a'), 3.02 (1H, *dd*, $J = 14.1, 8.7$ Hz, H-1b'); ^{13}C -NMR ($DMSO-d_6$, 125 MHz) δ : 124.2 (C-2), 109.5 (C-3), 118.3 (C-4), 118.4 (C-5), 120.9 (C-6), 111.4 (C-7), 127.3 (C-3a), 136.4 (C-7a), 27.2 (C-1'), 54.7 (C-2'), 171.0 (C-3').

Glycerine (13): Colorless viscous liquid; 1H -NMR (CD_3OD , 500 MHz) δ : 3.64 (1H, *m*), 3.58 (2H, *dd*, $J = 11.2, 4.9$ Hz), 3.51 (2H, *dd*, $J = 11.2, 6.0$ Hz); ^{13}C -NMR (CD_3OD , 125 MHz) δ : 73.8 (*d*, C-2), 64.4 (*t*, C-1, C-3).

Monoheneicosanoin (14): White amorphous powder; 1H -NMR ($CDCl_3$, 500 MHz) δ : 4.20 (1H, *dd*, $J = 12.0, 5.0$ Hz, H-1a), 4.15 (1H, *dd*, $J = 11.5, 5.5$ Hz, H-1b), 3.93 (1H, *m*, H-2), 3.69 (1H, *dd*, $J = 11.5, 6.0$ Hz, H-3a), 3.59 (1H, *dd*, $J = 11.5, 6.0$ Hz, H-3b), 2.35 (1H, *t*, $J = 7.5$ Hz, H-2'), 1.63 (2H, *m*, H-3'), 1.33 (34H, *br s*, H-4' - H-20'), 0.88 (3H, *t*, $J = 7.0$ Hz, H-21); ^{13}C -NMR ($CDCl_3$, 125 MHz) δ : 174.5 (C-1'), 70.4 (C-2), 65.3 (C-1), 63.5 (C-3), 34.3 (C-2'), 32.1 (C-19'), 29.3-29.8 (C-4' - C-18'), 25.1 (C-20'), 14.3 (C-21'); EI-MS m/z (rel. int.): 400 $[M]^+$ (25), 382 $[M - H_2O]^+$ (35), 369 $[M - CH_2OH]^+$ (36), 359 (34), 341 (92), 327 (38), 313 (9), 298 (15), 285 (32), 267 (95), 241 (14), 213 (17), 185 (24), 161 (21), 140 (29), 134 (36), 129 (36), 112 (39), 98 (58), 83 (48), 69 (63), 57 (92), 43 (100).

S3: HR-ESI-MS (positive) spectrum of compound 1

Elemental Composition Report

Page 1

Tolerance = 10.0 PPM / DBE: min = -1.5, max = 50.0
 Selected filters: None

Monoisotopic Mass, Even Electron Ions

8 formula(e) evaluated with 1 results within limits (up to 50 closest results for each mass)

Elements Used:

C: 5-10 H: 5-20 O: 1-8 Na: 1-1 S: 1-1

SIPI

XR-3 M.W.=186

Q101031H2 64 (2.257) AM (Cen,6, 80.00, Ar,5000.0,213.14,0.70); Sm (SG, 2x3.00); Cm (51:65)

Q-ToF micro

YA019


209.0250

17-May-2010,13:53:18

0.00000000

TOF MS ES+


2.78e4




Minimum: 35.00
 Maximum: 100.00

Mass	RA	Calc. Mass	mDa	PPM	DBE	i-FIT	Formula
209.0250	100.00	209.0248	0.2	1.0	3.5	5.8	C8 H10 O3 Na S


S4: EI-MS spectrum of compound 1




S5: $^1\text{H-NMR}$ (500 MHz, CD_3OD_3) spectrum of compound **1**




S6: $^{13}\text{C-NMR}$ (125 MHz, CD_3OD_3) spectrum of compound **1**



S7: DEPT135 spectrum of compound 1




S8: HSQC spectrum of compound 1




S9: HMBC spectrum of compound 1

HMBC xr-3 MeOD 12.1mg/0.5ml zipai weirongwan
E:/2010 100518-xijing-wxy




S10: ^1H - ^1H COSY spectrum of compound 1


COSY xr-3 MeOD 12.1mg/0.5ml zipai weirongwan
E:/2010 100518-xijing-wxy




S11: ESI-MS (positive) spectrum of compound 2




S12: EI-MS spectrum of compound 2



S15: DEPT135 spectrum of compound 2




S16: HSQC spectrum of compound 2



S17: HMBC spectrum of compound 2

HMBC XR-18 DMSO 3mg/0.6ml
E:/2010 100625-xijing-txr



S18: ^1H - ^1H COSY spectrum of compound 2

COSY XR-18 DMSO 3mg/0.6ml
E:/2010 100625-xijing-txr

